BackgroundThis study aims to assess the adverse events (AEs) and safety profile of omeprazole, a widely used proton pump inhibitor (PPI) for acid-related diseases. Despite being a first-line treatment
*Grade 3/4 adverse events summarised by MedDRA System Organ Class which were reported by 5 or more peoplepy: person yearsClinical outcomes by randomised arm.
Pyrogens, which include endotoxin and non-endotoxin pyrogens (NEPs), act on immune cells in the bloodstream, causing various effects such as fever and endotoxic shock. The limulus amebocyte lysate tes
